Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2023 | Brexu-cel in the treatment of R/R MCL: insights from the ZUMA-2 and ZUMA-18 trials

Max Topp, MD, University Hospital Wurzburg, Wurzburg, Germany, discusses the efficacy of brexucabtagene autoleucel (brexu-cel), an anti-CD19 CAR-T product, in relapsed/refractory (R/R) mantle cell lymphoma (MCL), which has been evaluated in the ZUMA-18 (NCT04162756) and ZUMA-2 (NCT02601313) trials. The findings indicate a high overall response rate (ORR), which is durable over 47.5 months, with manageable toxicity profiles. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.